enGene drops preclinical cystic fibrosis program to strengthen bladder cancer strategy

EnGene is halting work on a cystic fibrosis program to focus resources on moving its lead candidate further into bladder cancer.

The Canadian company is already testing the nonviral, intravesical therapy, known as detalimogene voraplasmid or EG-70, in the phase 2 LEGEND study for patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG). EnGene’s current goal is to submit EG-70 to the FDA for approval in 2026.